Palouse Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.23M | Sell |
92,603
-6,465
| -7% | -$169K | 1.39% | 31 |
|
|
2026
Q1 | $2.78M | Sell |
99,068
-1,568
| -2% | -$41.7K | 1.84% | 20 |
|
|
2025
Q4 | $2.51M | Sell |
100,636
-3,945
| -4% | -$99.5K | 1.61% | 26 |
|
|
2025
Q3 | $2.66M | Buy |
104,581
+2,735
| +3% | +$67.5K | 1.69% | 23 |
|
|
2025
Q2 | $2.47M | Sell |
101,846
-45,922
| -31% | -$1.07M | 1.63% | 28 |
|
|
2025
Q1 | $3.74M | Buy |
147,768
+10,816
| +8% | +$283K | 2.56% | 12 |
|
|
2024
Q4 | $3.63M | Sell |
136,952
-9,561
| -7% | -$259K | 2.42% | 10 |
|
|
2024
Q3 | $4.24M | Sell |
146,513
-2,746
| -2% | -$80.1K | 2.68% | 6 |
|
|
2024
Q2 | $4.18M | Sell |
149,259
-2,544
| -2% | -$70K | 2.8% | 3 |
|
|
2024
Q1 | $4.21M | Sell |
151,803
-5,273
| -3% | -$146K | 2.78% | 6 |
|
|
2023
Q4 | $4.52M | Buy |
157,076
+57,476
| +58% | +$1.74M | 3.2% | 3 |
|
|
2023
Q3 | $3.3M | Sell |
99,600
-1,262
| -1% | -$44.6K | 2.45% | 9 |
|
|
2023
Q2 | $3.7M | Buy |
100,862
+8,637
| +9% | +$336K | 2.59% | 7 |
|
|
2023
Q1 | $3.76M | Buy |
92,225
+24,868
| +37% | +$1.07M | 2.54% | 7 |
|
|
2022
Q4 | $7.07M | Sell |
67,357
-4,327
| -6% | -$207K | 0.49% | 52 |
|
|
2022
Q3 | $3.14M | Sell |
71,684
-24,783
| -26% | -$1.2M | 1.78% | 22 |
|
|
2022
Q2 | $5.06M | Sell |
96,467
-127
| -0.1% | -$6.47K | 2.51% | 6 |
|
|
2022
Q1 | $5M | Sell |
96,594
-1,153
| -1% | -$59.8K | 2.2% | 11 |
|
|
2021
Q4 | $5.77M | Sell |
97,747
-2,664
| -3% | -$132K | 2.47% | 9 |
|
|
2021
Q3 | $4.32M | Sell |
100,411
-2,058
| -2% | -$91.2K | 1.92% | 16 |
|
|
2021
Q2 | $4.01M | Sell |
102,469
-1,185
| -1% | -$46.1K | 1.75% | 20 |
|
|
2021
Q1 | $3.75M | Buy |
+103,654
| New | +$3.68M | 1.66% | 25 |
|
|
2018
Q3 | – | Sell |
-241,538
| Closed | -$8.31M | – | 110 |
|
|
2018
Q2 | $8.31M | Sell |
241,538
-5,102
| -2% | -$174K | 2.82% | 2 |
|
|
2018
Q1 | $8.3M | Sell |
246,640
-4,697
| -2% | -$161K | 2.76% | 2 |
|
|
2017
Q4 | $8.64M | Sell |
251,337
-1,288
| -0.5% | -$43.9K | 2.92% | 2 |
|
|
2017
Q3 | $8.56M | Sell |
252,625
-2,210
| -0.9% | -$71K | 2.86% | 2 |
|
|
2017
Q2 | $8.12M | Sell |
254,835
-1,040
| -0.4% | -$32.8K | 2.95% | 3 |
|
|
2017
Q1 | $8.3M | Buy |
255,875
+3,479
| +1% | +$110K | 3.15% | 2 |
|
|
2016
Q4 | $7.78M | Sell |
252,396
-2,260
| -0.9% | -$69K | 3.18% | 4 |
|
|
2016
Q3 | $8.18M | Sell |
254,656
-2,840
| -1% | -$95K | 3.48% | 1 |
|
|
2016
Q2 | $8.6M | Sell |
257,496
-5,683
| -2% | -$181K | 3.5% | 1 |
|
|
2016
Q1 | $7.4M | Buy |
+263,179
| New | +$7.52M | 3.02% | 2 |
|
Other funds holding PFE
AIM
SLAM
CWP
Palouse Capital Management's PFE Position: Q2 2026 in Review
Palouse Capital Management reduced its Pfizer (PFE) stake by 6.5% in Q2 2026, selling an estimated $169K and leaving 92,603 shares worth $2.23M. The position accounts for 1.39% of the portfolio, ranked #31.
Palouse Capital Management first reported a position in PFE in Q1 2016 and has held it in 32 quarters since. The position peaked at $8.64M in Q4 2017. 1,336 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Palouse Capital Management held 92,603 shares of Pfizer worth $2.23M as of Q2 2026.
- Palouse Capital Management sold 6,465 Pfizer shares in Q2 2026, an estimated $169K.
- Pfizer made up 1.39% of Palouse Capital Management's portfolio in Q2 2026, its #31 holding.
- Palouse Capital Management first reported a position in Pfizer in Q1 2016 and has held it in 32 quarters since.
- Palouse Capital Management's Pfizer position peaked at $8.64M in Q4 2017.
- 1,336 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Palouse Capital Management's 13F filing for Q2 2026, filed 8 Jul 2026.